Could a common asthma drug protect preemie lungs?
NCT ID NCT07101640
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 31 times
Summary
This study tests montelukast, an asthma drug, in 28 premature infants at high risk for bronchopulmonary dysplasia (BPD), a serious lung condition. Researchers want to see if the drug is safe and how it moves through the body. The infants receive montelukast or a placebo daily for up to 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Arkansas Children's Hospital
RECRUITINGLittle Rock, Arkansas, 72202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
East Carolina University
RECRUITINGGreenville, North Carolina, 27858, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Center of Southern Nevada
RECRUITINGLas Vegas, Nevada, 89102, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Massachusetts
RECRUITINGAmherst, Massachusetts, 01003, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of North Carolina (UNC)
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
montelukast
What this could lead to
If it works, this could point toward a treatment to reduce lung damage in premature infants with bronchopulmonary dysplasia.
What could go wrong
This is an early phase 1/2 trial with only 28 infants, so it is too small to prove effectiveness. The optimal dose is still unknown, and the drug may not provide clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.